SCIENTURE REPORTS Q3 2026 RESULTS WITH APPROXIMATELY 265% SEQUENTIAL REVENUE GROWTH DRIVEN BY THE COMMERCIAL LAUNCH OF REZENOPY™
SCIENTURE REPORTS Q3 2026 RESULTS WITH APPROXIMATELY 265% SEQUENTIAL REVENUE GROWTH DRIVEN BY THE CO
SCIENTURE REPORTS Q3 2026 RESULTS WITH APPROXIMATELY 265% SEQUENTIAL REVENUE GROWTH DRIVEN BY THE CO